Atopic Dermatitis
Conditions
Interventions
This is a two-arm, double-blind, randomized controlled clinical trial. Experimental group: 36 people with atopic dermatitis will receive topical administration of a cream containing 10% K. brasiliensi
D23.704
Sponsors
Universidade de Ribeirão Preto - UNAERP
Universidade de Ribeirão Preto - UNAERP
Eligibility
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Male or female with mild atopic dermatitis aged 18 to 70 years on at least monotherapy regimen for this disease; Present SCORAD (Scoring of Atopic Dermatitis) with a value lower than 25; Potentially fertile women will be allowed to participate in the study as long as they are using at least one form of birth control
Exclusion criteria
Exclusion criteria: Pregnant or breastfeeding women; Participants who during treatment need to use systemic corticosteroids and/or anti-inflammatory and/or other topical medications; Individuals with a known allergy to plants of the Crassulaceae family or components of the formula; Request, at any time, by the participant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that the effects of Kalanchoe brasiliensis cream in adults with atopic dermatitis will be effective, promoting symptom relief, improving quality of life and preventing exacerbations. The parameters used will be SCORAD (Scoring of Atopic Dermatitis) and EASI (Eczema Area and Severity Index). | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected that the effect of the phytotherapeutic reduce the symptoms of burning and itching caused by atopic dermatitis. The parameters used will be BSA (Body Surface Area) e vIGA-AD (The Validated Investigator Global Assessment for Atopic Dermatitis). | — |
Countries
Brazil
Contacts
Public ContactPedro Amatto Goulart
Universidade de Ribeirão Preto - UNAERP
Outcome results
None listed